AsymBio to secure $184m from Asymchem Group, Hillhouse Qirui and others

M&A · Partnership
โดย Pharmaceutical Technology·CN·Read original
Summary · why it matters

Biologics CDMO AsymBio is set to secure 1.2397 billion yuan, approximately $184 million, from Asymchem Group, Hillhouse Qirui and other investors to support its long-term growth. Asymchem Group will contribute 1.05 billion yuan while Hillhouse Qirui will invest 177 million yuan, with Asymchem Group's shareholding in AsymBio rising to 83.4965 percent after the transaction. The funds will be used for AsymBio's principal business operations and to drive further expansion of its manufacturing capacity, including research and development capabilities, GMP manufacturing lines, and high-containment facilities. AsymBio generated 470 million yuan in revenue during 2025, with revenue for the first quarter of 2026 exceeding 140 million yuan. The company operates as a subsidiary of Asymchem Group and focuses on biopharmaceutical CDMO services from early-stage development to large-scale commercial manufacturing, with experience in ADCs and expansion into NDCs and protein-based therapeutics.

Impact on stocks 1

Others▲ · 1 stocks

Theme Impact 1

Off-coverage companies 2

AsymBioPrivate▲ Positive
Capitalrelevance

AsymBio secures $184m funding from Asymchem Group, Hillhouse Qirui and others to expand manufacturing capacity and operations.

Hillhouse QiruiPrivate▲ Positive
Capitalrelevance

Hillhouse Qirui invests 177 million yuan in AsymBio, participating in the funding round.

Related news

Avantor Expands RIM Single-Use Bioprocessing Portfolio Across APAC

Avantor has expanded the availability of its RIM single-use bioprocessing portfolio across the Asia Pacific region, strengthening its presence in a key biopharma manufacturing market. The portfolio includes single-use consumables such as bioprocessing bags, assemblies, tubing and components, plus mixing and storage hardware, and is manufactured at Avantor's Changzhou, China facility, the company's first single-use production site in APAC. That 2,600-square-meter plant operates under ISO 9001:2015 certification and Good Manufacturing Practice standards, and RIM products are available exclusively to APAC customers. The move aligns with management's broader Revival strategy, and in the second quarter of 2026 the Bioscience & Medtech Products segment posted double-digit order growth and a book-to-bill ratio of 1.1x, with management expecting the segment to return to organic growth in the second half of 2026. Avantor currently has a market capitalization of $10.56 billion, and its shares have gained 38.4% year to date versus 3.4% growth for the industry and a 10.1% rise in the S&P 500.
AVTR ▲
Biotech & Genomic Medicine
Zacks Investment Research·16hRead more →
▲

Andelyn Begins Commercial Manufacturing of Ultragenyx's FDA-Approved FAYUVI Gene Therapy

Andelyn Biosciences announced it is now manufacturing FAYUVI, Ultragenyx Pharmaceutical Inc.'s FDA-approved gene therapy for Sanfilippo syndrome type A, also known as mucopolysaccharidosis type IIIA, for commercial supply at its Columbus, Ohio facility. The move follows the U.S. Food and Drug Administration's approval of FAYUVI, making it the first FDA-approved gene therapy manufactured using the Andelyn AAV Curator Platform process. Sanfilippo syndrome type A is a rare, fatal lysosomal storage disease that primarily affects the central nervous system and is marked by rapid neurodegeneration beginning in early childhood; it is estimated to affect 3,000 to 5,000 patients worldwide, with a median life expectancy of 15 years. Andelyn Chief Executive Officer Wade Macedone said the company is proud to manufacture an FDA-approved gene therapy for commercial use using an AAV Curator Platform process, calling the milestone a reflection of the purpose behind Andelyn's founding. Andelyn, a full-service FDA-inspected cell and gene therapy commercial CDMO with more than 20 years of experience, has produced clinical and commercial material for more than 500 cGMP batches and 85 global clinical trials.
RARE ▲
Biotech & Genomic Medicine ▲
PR Newswire·18hRead more →
▲2

Charles River Laboratories Launches Rapid Cell Banking Platform With 40% Faster Production

Charles River Laboratories International unveiled new rapid cell banking and release programs that use advanced sequencing and in vitro tools to shorten biologics and advanced therapy cell bank lead times for biopharma clients. The platform cuts cell bank production time by 40% and combines rapid microbiological methods with NGS characterization, including the iDTECT NGS platform, to support regulatory readiness. Charles River says the approach reduces reliance on animal testing by incorporating alternative in vitro methods aligned with the 3Rs framework. The company, a US life sciences group with a market cap of about $13.1b, positions the offering for time-sensitive programs where delays are costly. Investors will watch for booked projects using the iDTECT NGS platform, client mix in advanced therapies, and whether the services appear in updated segment revenue breakdowns.
CRL
Biotech & Genomic Medicine ▲
Simply Wall St·21hRead more →
© 2026 MarketDXNews